Alligator Bioscience AB’s Post

Attending #MSACL2024 in Monterey?! Make sure you stop by booth #21 to learn how SCIEX's LC-MS/MS solutions can help you advance your work in #clinical research and diagnostics. And make sure to check out our posters in the Exhibit Hall (Serra) showcasing the latest clinical applications. #ClinicalAnalysis #InnovationMatters #EducationMatters SCIEX is presenting 3 posters on the following topics: -High-resolution mass spectrometry peptide quantitation for biomarker verification with limited method development (Poster #10b) -Quantitative and qualitative analysis of steroids with simplified sample preparation (Poster #4a) -Development of highly sensitive analytical techniques for the detection of galactosylsphingosine (GalSPH) and glucosylsphingosine (GluSPH) in cerebral spinal fluid (Poster #4b) Advance your clinical knowledge with our posters from MSACL 2024! https://bit.ly/4a4Axx0

We're thrilled to share our latest research on Conditional Average Treatment Effects (CATE) estimation in clinical trials. CATE estimation provides crucial value of understanding treatment effect heterogeneity, which is inherent to designing patient-centered trials. Our extensive simulation study demonstrates the limitation of traditional methods and introduces novel ensemble methods, which present better results across diverse use cases, varying in complexity, sample size, and underlying mechanisms. These robust methods reveal the factors driving heterogeneity in the presence of multiple covariates and complex biological signals, across therapeutic areas and trial types. Understanding the factors driving the heterogeneity enables us to predict treatment effects and probability of success and extract actionable, clinically significant, and business-meaningful insights to maximize the success of the next trial. Oshri Machluf Raviv Pryluk Elad Berkman Tzviel Frostig Gal Shoham Levin Tomer Milo

Very proud to share some of the work we've been busy with, led by Oshri Machluf, Tzviel Frostig, Tomer Milo, Gal Shoham Levin and Raviv Pryluk. Our preprint on Robust CATE Estimation Using Novel Ensemble Methods is now available on arXiv! Causal Machine Learning for CATE estimation is a new and promising approach for identifying heterogeneous treatment effects and promising subgroups in clinical trials. Originally developed in the econometrics domain, this multi-disciplinary approach combines Causal Inference, Machine Learning, and Statistics. In this paper, we compare existing methods across a wide range of scenarios specifically tuned for clinical trials and propose two novel methods with improved robustness. As part of this work, we developed a unique Causal Biological Model of the PD-L1 pathway, trained on real clinical data, and used it to create more realistic data for our benchmarking. This is yet another example of how integrating biology and machine learning can drive innovation. Excited to see the impact this will have on the future of clinical trials!

Excited to share that the final version of our manuscript "Concizumab improves clot formation in hemophilia A under flow" is now available online! 📚🔬 Check it out here: https://lnkd.in/gUXKbVtB #Research #MedicalScience

I'm excited to share that we will present at the upcoming Society for Immunotherapy of Cancer (SITC) conference, showcasing our AI-based metabolomics platform and findings! PBRM1 is the second most mutated gene in clear-cell renal cell carcinoma; however, previous clinical trials have shown conflicting results regarding its association with responses to cancer immunotherapy. Our research has discovered that patients with PBRM1 mutations respond to immune checkpoint inhibitor (ICI) therapy contingent on their metabolic subtypes. These findings help explain the inconsistent reports about PBRM1 mutations and ICI responses. They also suggest that metabolomics provides complementary information to genetics in predicting the outcomes of cancer immunotherapy. #AI #Metabolomics #Genomics #Immunotherapy #DataIntegration #PrecisionMedicine #SITC2024 https://lnkd.in/gAJRG67U

𝗧𝗵𝗲 𝗴𝘂𝘆𝘀 𝗵𝗮𝘃𝗲 𝗴𝗮𝘁𝗵𝗲𝗿𝗲𝗱 𝘀𝗼𝗺𝗲 𝗽𝗿𝗶𝗻𝗰𝗶𝗽𝗹𝗲𝘀 𝗮𝗻𝗱 𝗯𝘂𝗶𝗹𝘁 𝗮 𝗹𝗼𝗴𝗶𝗰 𝗳𝗼𝗿 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝗻𝗴 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿𝘀 𝗳𝗼𝗿 𝗮 𝗰𝗲𝗿𝘁𝗮𝗶𝗻 𝗰𝗮𝗻𝗰𝗲𝗿 𝗻𝗼𝘀𝗼𝗹𝗼𝗴𝘆. If this logic is the basis for LIMS, it could be a compromise between two aspirations: to make medicine a craft with clear rules and the reluctance of the physician, with his art and experience, to follow outside laboratory guidelines. Creating shared rules for test prescribing can help in many controversial cases - https://lnkd.in/g-tWxcdF #ADLM #CanserNosology #LIMS #VivicaLIMS #LifeDataLab https://about.vivica.us https://lifedl.net

Cardioprotective properties of OMEICOS lead OMT-28 - interesting new paper out in JBC with mechanistic insights into MoA - take the ride, it is quite interesting #SIRT1 #MitochondrialDysfunction #Cardiomyopathy

Good to read!!! ⚈Deucravacitinib (Sotyktu) - A deuterium-containing small molecule for psoriasis. ⚈Mavacamten (Camzyos) - A pyrimidinedione derivative for hypertrophic cardiomyopathy. ⚈Mitapivat (Pyrukynd) - A pyruvate kinase activator for hemolytic anemia in pyruvate kinase deficiency. ⚈Vonoprazan (used in combination therapies) - A potassium-competitive acid blocker for H. pylori infection. ⚈Taurursodiol and sodium phenylbutyrate (Relyvrio) - Combined for ALS treatment. ⚈Oomidenepag isopropyl (Eybelis) - A prostaglandin E2 receptor agonist for glaucoma. ⚈Lecanemab (Leqembi) - Approved early in 2023 for Alzheimer’s, following critical advancements from 2022 research. ⚈Abrocitinib - A Janus kinase inhibitor for atopic dermatitis The majority of authorized medications (31%) are used to treat cancer. This includes, among other conditions, non-Hodgkin lymphoma, non-small cell lung cancer, relapsed or refractory acute myeloid leukemia, platinum-resistant ovarian cancer that recurs, and incurable hepatocellular carcinoma.

QurAlis looks forward to delivering several presentations on our clinical programs in #ALS at the 35th International Symposium on ALS/MND. Presentations include an update on our Phase 1 ANQUR clinical trial evaluating QRL-201 for the treatment of ALS. ANQUR is the first-ever clinical trial to evaluate a potential therapy to rescue #STATHMIN-2 expression in people with ALS. QurAlis recently announced that ANQUR completed the dose-escalation phase, based on PK data analysis from Cohorts 1 and 2, indicating CSF exposure levels of QRL-201 met or exceeded the targeted therapeutic range. The ANQUR clinical trial has advanced to the dose range-finding (DRF) phase which will evaluate two doses of QRL-201 and include additional #biomarkers. The study design will now also include a cohort of participants with #C9orf72-related ALS in addition to participants with sporadic ALS. The ANQUR clinical trial is currently active in Canada, the UK, and the EU. The first participant in the DRF phase has been dosed in Canada. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases https://bit.ly/3ZCfNtQ

Our team will be presenting six studies https://bit.ly/3AcB1Vg at SITC 2024 in Houston, and I'm proud to be involved in three of them. As a pathologist and project manager, it's been amazing working with such a talented groups. We've been diving deep into cancer research, using genomic profiling and MXIF imaging to better understand and fight cancer. Feel free to visit us at Level 1 - Exhibit Halls AB (George R. Brown Convention Center) on November 8 and 9 at the start of the conference to connect and discuss our presentations: 1. "Identifying Novel Targets for Antibody-Drug Conjugates in Sarcomas Using RNA Sequencing" We're using RNA sequencing to find new targets for antibody-drug conjugates in our cohort of up to 800 sarcoma patients. By looking at gene expression and the tumor microenvironment, we're aiming to improve therapies for these tough cancers. 2. "Comprehensive Molecular Profiling in the Management of Patients with Diverse Sarcoma Subtypes" This work shows how genomic profiling can help refine diagnoses and personalize treatment for sarcoma patients with potentially actionable alterations, particularly kinase gene rearrangements and many others. 3. "Multiplex Immunofluorescence of Whole Slide Images for Enhanced Tumor Microenvironment Immune Cell Characterization in Multiple Cancer Types". In this study, we're using cutting-edge imaging to get a closer look at the immune cells in different cancers using BG tools (check the recent BG publication in Blood to know more about it https://bit.ly/48i4Yji). It's pretty cool stuff that helps us understand how tumors interact with the immune system. Whether you're into sarcomas, immunotherapy, advanced imaging techniques, or just passionate about pushing the boundaries of oncology, let's meet up. #SITC2024 #BostonGene #CancerResearch #PrecisionOncology #Sarcoma #GenomicProfiling #Immunotherapy #TumorMicroenvironment #MXIF